MIMEDX Group, Inc.

MIMEDX Group, Inc. Patients are why we are here. MIMEDX has supplied over two million allografts, through both direct and consignment shipments.

MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a core business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. For additional information, please visit www.mimedx.com.

EPIFIX® has been studied across multiple prospective, multicenter, randomized controlled trials. The results are consist...
09/09/2026

EPIFIX® has been studied across multiple prospective, multicenter, randomized controlled trials. The results are consistent: meaningfully better closure rates and outcomes that hold up against both the standard of care and leading competitors.

5 of the 12 low-risk-of-bias RCTs identified in the 2020 Agency for Healthcare Research and Quality (AHRQ) technical review, across all skin substitute manufacturers, were MIMEDX studies.

When TIME'S UP at week 4, clinicians deserve evidence they can trust. Learn more about EPIFIX: https://mimedx.info/EPIFIX

A retrospective, multicenter study published in the European Surgical Research Journal¹ evaluated 30-day outcomes in com...
09/08/2026

A retrospective, multicenter study published in the European Surgical Research Journal¹ evaluated 30-day outcomes in complicated diverticulitis patients receiving AMNIOFIX® as a protective barrier after colectomy anastomosis, referencing the ACS-NSQIP national database² for context. The datasets were not statistically compared.

•3.9% 30-day readmission rate with AMNIOFIX¹ vs. 6.7% in the ACS-NSQIP benchmark²
•1.7% reoperation rate with AMNIOFIX¹ vs. 3.2% in the ACS-NSQIP benchmark²

Learn more and read the clinical summary based on the published manuscript: https://mimedx.info/colorectal-and-general-surgery

1. Das B, et al. Eur Surg Res. 2026;67:81–91. 2. Ore AS, et al. Am Surg. 2023;89(11):4590-4597.

Disclosures: To provide contextual reference, the authors identified contemporary benchmarks from the peer-reviewed literature that most closely resembled the AMNIOFIX cohort in this study. The authors of this study are paid consultants of MIMEDX Group, Inc.

Not all PRP preparations are the same. Platelet concentration, red blood cell content, and cellular balance can all play...
09/02/2026

Not all PRP preparations are the same. Platelet concentration, red blood cell content, and cellular balance can all play a role in the chronic wound environment. Explore the new Product in Practice module on Wound Care Today USA and take a closer look at the science behind RegenKit®-Wound Gel.

✔Chronic wound biology
✔PRP composition
✔Point-of-care workflow

Start learning today: https://mimedx.info/PRP-Product-In-Practice

WCT USA

A retrospective, multicenter study published in the European Surgical Research Journal¹ compared outcomes in complicated...
09/01/2026

A retrospective, multicenter study published in the European Surgical Research Journal¹ compared outcomes in complicated diverticulitis patients who received AMNIOFIX® as a protective barrier after colectomy anastomosis using a contemporary standard-of-care benchmark from the published literature.²

•1.7% anastomotic leak rate with AMNIOFIX¹ vs. 6.6% in the standard-of-care benchmark²
•1.7% reoperation rate with AMNIOFIX¹ vs. 11.3% in the standard-of-care benchmark²

Learn more and read the clinical summary based on the published manuscript: https://mimedx.info/colorectal-and-general-surgery

1. Das B, et al. Eur Surg Res. 2026;67:81–91. 2. Beltzer C, et al. Adv Surg Tech A. 2019;29(11):1451-1455.

Disclosures: To provide contextual reference, the authors identified contemporary benchmarks from the peer-reviewed literature that most closely resembled the AMNIOFIX cohort in this study. The authors of this study are paid consultants of MIMEDX Group, Inc.

08/27/2026

"A tremendous time saver." That's how Jeff Kingery, Chief Clinical Officer at WoundGenex, describes ordering with MIMEDX Connect.

"It is a tremendous time saver to work in Connect because there is no longer the need to dial up somebody and have a conversation. You simply log in, enter your data, and press submit, and the information flows."

Explore MIMEDX Connect: https://mimedx.info/connect

In surgery, every minute matters.AMNIOFIX® Thyroid Shields combine preconfigured sizing and easy application to help str...
08/26/2026

In surgery, every minute matters.

AMNIOFIX® Thyroid Shields combine preconfigured sizing and easy application to help streamline thyroid procedures while delivering advanced protection on exposed tissues.

Precision. Efficiency. Science. Learn more: https://mimedx.info/Thyroid-Surgery

Many wounds that are failing to close are stuck in inflammation, and that’s where RegenKit®-Wound Gel autologous PRP the...
08/25/2026

Many wounds that are failing to close are stuck in inflammation, and that’s where RegenKit®-Wound Gel autologous PRP therapy comes in.

Chronic wounds often stall in a prolonged inflammatory state, where dysregulated leukocyte activity and elevated protease levels have been associated with delayed progression toward healing. In that environment, the composition of the PRP you introduce matters.

Explore a new Product in Practice module on Wound Care Today USA to learn how RegenKit®-Wound Gel is prepared at the bedside from a small blood draw, the science behind its use, and the evidence supporting its role in wound management.

Interact with the module now: https://mimedx.info/PRP-Product-In-Practice

WCT USA

RegenKit®–Wound Gel, our autologous PRP wound gel prepared at the point of care, is now available through the MIMEDX par...
08/20/2026

RegenKit®–Wound Gel, our autologous PRP wound gel prepared at the point of care, is now available through the MIMEDX partnership with WoundGenex. This program, offered by WoundGenex, supports timely patient access to advanced wound care technology by removing financial barriers.

🔗 Learn more and reach out to a WoundGenex rep: https://mimedx.info/WoundGenex-Partner-Site

08/18/2026

Your reimbursement workflow, simplified. MIMEDX Connect helps you track IVRs, stay ahead of reimbursement news, and access audit support and analytics, all in one place.

Explore MIMEDX Connect: https://mimedx.info/connect

Not every wound is straightforward. G4Derm® Plus is designed for the ones that aren't.Flowable. Acellular. Precise. This...
08/17/2026

Not every wound is straightforward. G4Derm® Plus is designed for the ones that aren't.

Flowable. Acellular. Precise. This biomimetic extracellular matrix (ECM) supports healing, guards the wound bed with an antibacterial barrier,* and reaches where treatment is needed — even in deeper voids and undermining areas.

Learn more: https://mimedx.info/G4Derm-Plus

*Data on File, FDA 510(k) submission package. Antibacterial Barrier Effectiveness of G4Derm Plus. Gel4Med, Inc.

Distributed by MIMEDX. Owned and manufactured by Gel4Med Inc.

Address

Atlanta, GA

Telephone

+17706519100

Website

Alerts

Be the first to know and let us send you an email when MIMEDX Group, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category